The latest price target for BeiGene (NASDAQ:BGNE) was reported by Morgan Stanley on December 3, 2024. The analyst firm set a price target for $300.00 expecting BGNE to rise to within 12 months (a possible 69.40% upside). 14 analyst firms have reported ratings in the last year.

The latest analyst rating for BeiGene (NASDAQ:BGNE) was provided by Morgan Stanley, and BeiGene their overweight rating.

The last upgrade for BeiGene Ltd happened on October 13, 2022 when Guggenheim raised their price target to $205. Guggenheim previously had a neutral for BeiGene Ltd.

The last downgrade for BeiGene Ltd happened on June 30, 2023 when Bernstein changed their price target from $335 to $196 for BeiGene Ltd.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of BeiGene, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for BeiGene was filed on December 3, 2024 so you should expect the next rating to be made available sometime around December 3, 2025.

While ratings are subjective and will change, the latest BeiGene (BGNE) rating was a with a price target of $0.00 to $300.00. The current price BeiGene (BGNE) is trading at is $177.10, which is within the analyst’s predicted range.